Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

07:15
10/06/16
10/06
07:15
10/06/16
07:15

Alnylam price target lowered to $58 from $86 at Jefferies

Jefferies analyst Gena Wang lowered her price target for Alnylam Pharmaceuticals to $58 from $86 following the termination of revusiran Phase 3 due to mortality imbalance. The analyst believes the setback, while "major," is likely to be program specific and not impact the company's other trials. She keeps a Buy rating on Alnylam.

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

10/06/16
PIPR
10/06/16
NO CHANGE
Target $106
PIPR
Overweight
Alnylam selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff views today's selloff in shares of Alnylam Pharmaceuticals after the company discontinued its revusiran program as a buying opportunity. The analyst does not believe the discontinuation has read-through to the Phase III APOLLO trial or seven other RNAi drugs that employ ESC-GalNAc technology. He lowered his price target for Alnylam shares to $106 from $118 and keeps an Overweight rating on the name. JPMorgan and Barclays this morning downgraded the shares.
10/06/16
LEER
10/06/16
DOWNGRADE
Target $40
LEER
Market Perform
Alnylam downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Alnylam Pharmaceuticals to Market Perform after the company discontinued development of revusiran. To reflect an increased level of uncertainty around the company's pipeline, the analyst cut his price target for the shares to $40 from $107. JPMorgan and Barclays also downgraded Alnylam this morning while Piper Jaffray recommends buying the stock on weakness.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/06/16
JEFF
10/06/16
NO CHANGE
Target $43
JEFF
Buy
Alnylam setback has no read-through to Medicines Co., says Jefferies
Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.

TODAY'S FREE FLY STORIES

PAA

Plains All American

$24.53

0.6301 (2.64%)

14:50
06/23/17
06/23
14:50
06/23/17
14:50
Options
Bullish long-term option play opened in Plains All American Pipeline »

Bullish long-term option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Nov

LION

Fidelity Southern

$22.59

0.01 (0.04%)

14:46
06/23/17
06/23
14:46
06/23/17
14:46
Hot Stocks
Fidelity Southern announces appointment of Charles Christy as CFO »

Fidelity Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

14:40
06/23/17
06/23
14:40
06/23/17
14:40
General news
Fedspeak will resume with Chair Yellen »

Fedspeak will resume with…

14:30
06/23/17
06/23
14:30
06/23/17
14:30
Options
Alerian MLP attracts call buyers as shares attempt to rebound »

Alerian MLP attracts call…

LITE

Lumentum

$62.45

-0.05 (-0.08%)

14:25
06/23/17
06/23
14:25
06/23/17
14:25
Options
Lumentum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

14:20
06/23/17
06/23
14:20
06/23/17
14:20
General news
Action Economics Survey results »

Action Economics Survey…

NTDOY

Nintendo

$42.05

0.435 (1.05%)

, SNE

Sony

$38.52

0.11 (0.29%)

14:17
06/23/17
06/23
14:17
06/23/17
14:17
Periodicals
Nintendo market cap surpasses Sony's in Japan, Nikkei reports »

Nintendo's (NTDOY)…

NTDOY

Nintendo

$42.05

0.435 (1.05%)

SNE

Sony

$38.52

0.11 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
06/23/17
06/23
14:17
06/23/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/23/17
06/23
14:16
06/23/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

14:15
06/23/17
06/23
14:15
06/23/17
14:15
Conference/Events
Portola Pharmaceuticals hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

SAFM

Sanderson Farms

$123.21

-2.89 (-2.29%)

14:08
06/23/17
06/23
14:08
06/23/17
14:08
Hot Stocks
Sanderson Farms to 'vigorously defend' California chicken lawsuit »

Sanderson Farms issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$60.50

3.847 (6.79%)

14:05
06/23/17
06/23
14:05
06/23/17
14:05
Options
Restoration Hardware call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
06/23/17
06/23
14:00
06/23/17
14:00
General news
Breaking General news story  »

Federal Reserve Board…

BLCM

Bellicum Pharmaceuticals

$13.98

1.33 (10.51%)

13:51
06/23/17
06/23
13:51
06/23/17
13:51
Recommendations
Bellicum Pharmaceuticals analyst commentary  »

Bellicum selloff after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Sep

MDRX

Allscripts

$12.71

0.52 (4.27%)

13:50
06/23/17
06/23
13:50
06/23/17
13:50
Options
Second day of bullish option flow in Allscripts »

Second day of bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$18.50

0.16 (0.87%)

13:45
06/23/17
06/23
13:45
06/23/17
13:45
Options
Nutanix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/23/17
06/23
13:40
06/23/17
13:40
General news
And now Fed's Mester warns that a failure to hike »

And now Fed's Mester…

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:36
06/23/17
06/23
13:36
06/23/17
13:36
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:35
06/23/17
06/23
13:35
06/23/17
13:35
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

GE

General Electric

$27.59

0.035 (0.13%)

13:30
06/23/17
06/23
13:30
06/23/17
13:30
Options
19.1K GE Jul - Aug 29 call spreads sold at 12c »

19.1K GE Jul - Aug 29…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:26
06/23/17
06/23
13:26
06/23/17
13:26
Hot Stocks
Portola Pharmaceuticals to resume trading at 1:35 pm ET »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

CHGG

Chegg

$12.44

0.48 (4.01%)

13:25
06/23/17
06/23
13:25
06/23/17
13:25
Recommendations
Chegg analyst commentary  »

Chegg price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
06/23/17
06/23
13:25
06/23/17
13:25
General news
Energy Action: Baker-Hughes »

Energy Action:…

VRX

Valeant

$15.58

0.0801 (0.52%)

13:20
06/23/17
06/23
13:20
06/23/17
13:20
Options
Valeant expiring options active Friday »

Valeant expiring options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

$NSD

NASDAQ Market Internals

13:17
06/23/17
06/23
13:17
06/23/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.